Regeneron Pharmaceuticals, Inc.
Net buyer this quarter
$177M
3
+$114M
100.0%
Holdings
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026 | |||||
 PBLS | $114M | 64.35% | 3.42% | New | Q2 2026 |
 NTLA | $62.7M | 35.35% | 2.64% | Not reported | Q4 2024 |
 ACET | $523K | 0.30% | 0.65% | Not reported | Q4 2024 |
| Q1 2026 | |||||
| NTLA | $47.5M | 99.14% | 3.07% | Not reported | Q4 2024 |
| ACET | $412K | 0.86% | 0.63% | Not reported | Q4 2024 |
| Q4 2025 | |||||
| NTLA | $33.3M | 98.49% | 3.18% | Not reported | Q4 2024 |
| ACET | $510K | 1.51% | 0.63% | 0.0% | Q4 2024 |
| Q3 2025 | |||||
 ALNY | $635M | 90.64% | 1.06% | -68.7% | Q4 2024 |
| NTLA | $64M | 9.13% | 3.20% | Not reported | Q4 2024 |
| ADVM | $820K | 0.12% | 0.86% | Not reported | Q4 2024 |
| ACET | $784K | 0.11% | 1.16% | Not reported | Q4 2024 |